Grandrent has long been in the world, and knows the cunning and ruthlessness of the market, whether it is the family left behind or the company he started himself, he has the power to control, from development to distribution, he has been tightly controlled, with superior business acumen, has achieved great results.

Smith solved his doubts about the problem that may violate the bottom line of human morality and ethics, and the reason why the current cloning research has caused this problem is that the embryonic stem cells they use are often to create embryos first, extract embryonic stem cells and then destroy the embryos, or nuclear transfer technology to clone embryonic stem cells, that is, implant the nucleus of somatic cells into an egg with the nucleus removed and redevelop into stem cells. The research under the auspices of Xue Yunchu has reactivated the division and development function of ordinary skin cells and re-formed embryonic stem cells without the participation of eggs, so there is no such concern at all. It can be said that it is a very simple therapeutic organ cloning, but even so, it will take a long time for what remains in the traditional concept of human beings to be removed by scientific explanation.

Of course, there is a good chance that this technology will be similarly banned, as it may be used to replicate other people. This is the most intolerable in society. Smith was also helpless when he said this, because they were already in the process of copying.

Is it possible to patent this technology to bring economic benefits? The market must be vast and lucrative, as can be seen from the number of patients who receive and wait for organ transplants each year, and the huge fees that hospitals charge from them, Grandrent thought after asking Smith.

He consulted with his legal experts, who pointed out that most countries do not grant patent protection to such technologies as medical methods, and although a few countries such as the United States and Australia provide patent protection for medical methods, the United States has also enacted legislation to prohibit research on cloning, and Australia passed a bill a few years ago to allow research on therapeutic cloning, but after a detailed examination of the patent bills provided by various countries in the field of biotechnology, it is difficult to apply for a patent for this kind of biomedical technology related to cloning. It is one thing to allow research, but it is another to legislate to protect the results of research. Other biomedical technologies do not have this restriction, such as gene therapy and nanomedicine, which may be protected by patents. In the final analysis, this is because this technology has the potential to violate human moral boundaries and social ethics, and just like Smith, it is also possible that it can be used to widely replicate others, at least it is conceivable that it will bring great disruption to the current DNA identification system, directly leading to the collapse of the latter.

Although the federal government itself does not invest in research into therapeutic cloning, he is aware of several consortia that are also doing it, albeit not as rapidly as it does.

In this way, after the publication, the benefits that can be obtained by themselves are very small, and the biggest impact may be to change the current negative attitude of most countries towards cloning.

If you conceal the existence of this technology for the sake of experimental secrecy, those researchers involved in this technology will definitely be dissatisfied, and the results of their hard work will not be recognized and honored by their peers, and even if they can give them how much money to compensate, I am afraid it will be difficult to eliminate this negative impact.

Fortunately, this is not his real purpose, and there are dozens of people who know about the overall research plan, and they are all tightly controlled.

He weighed the pros and cons repeatedly, but he couldn't make up his mind. If the research results that have been invested a huge amount of money are used by others for free, he feels like he has been dug up a piece of flesh.

He had to ask Smith again about the technology itself.

Smith wasn't surprised by his reaction, he was an investor in a project after all, and it must be uncomfortable to have results without seeing a return on the benefits.

After all, they had been friends for many years, and although Smith felt that this was somewhat inconsistent with his scientific ethics, he made a suggestion based on various considerations. Organ cloning laboratories have been established in countries where such techniques are permitted, while a hospital has been opened to provide less expensive cloned organs.

At the same time, as much as possible, we should apply for medical technology patents in other countries that allow organ cloning, such as the United Kingdom, to avoid losses as much as possible.

Such a huge market is about to be lost because it cannot monopolize technology alone, and Grandrent thinks that there is no better way.

After consulting with the expert group, after arguing for a long time, they finally came up with a better suggestion, first publish a part of the technology, break the common prejudice against therapeutic cloning research in the world, and then set up a sample site in a country to provide cheap cloned organ transplantation, and finally apply for a patent for this biomedical technology. Of course, some of the necessary technical concealment methods are still used in the same way as traditionally. If the patent cannot be approved, then the hospital should be opened in every country where cloning therapy is allowed, providing the same services, and the ultimate means of monopolizing the market distribution network to control this huge market. After all, the prerequisite investment and equipment required to clon organs is also a relatively large expenditure, and it is certainly impossible for them to independently research this technology in a short period of time, and in the case of not being able to seize enough market share, others should also consider participating in this competition.

Grandrent listened to their suggestions and felt that this could only be the case for the time being, but when it came to the technology itself, he still had to ask the person in charge.

After listening to Grandrent's words, Xue Yunchu felt that he could use this matter to solve the funding problem, so he said: "How to publish the technology, I can meet the needs of your plan, but according to the agreement we reached before, after the promotion and use of this technology, I have 20% of the profit distribution, Mr. Grandrent, don't forget." ”

"Of course, there is no problem with this, and the income in the future will be directly transferred to the doctor." Although Grandrent was a little heartbroken about giving away 20% of the profits, it was originally an additional product, and his ultimate goal was not here, so he didn't feel that there was anything more.

A week later, an article was published in the authoritative British academic weekly Nature that a privately funded laboratory in the United States had developed a new method for obtaining embryonic stem cells. People who read this didn't think that this was just the beginning.